Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer also announced a hefty total dividend of Rs 165 per equity share for FY25. This includes a final dividend of Rs 35 per ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

When companies post strong earnings, the stock generally performs well, just like Pfizer Inc.'s ( NYSE:PFE ) stock ...

Just don't jump to conclusions about a stock's probable future based on its recent (and not-so-recent) past, even when that historical weakness is as dramatic and prolonged as Pfizer's has been.

Last year was a strong one in terms of performance and execution by Pfizer, even though its stock took a hit in 2023 due to a decline in revenues and profits. It saw improved performance of its ...

But I actually see this as a risk factor since according to my earlier analysis, Pfizer ... company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pfizer’s PFE $13.7 billion in revenue (an ... Management said that full-year performance is trending toward the high end of EPS guidance. Cardiomyopathy drugs including Vyndaqel grew 31% ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.